PALI Stock Catalyst: Palisade Bio Completes SAD Cohorts and Starts MAD Cohorts in PALI-2108 Trial

Jan 15, 2025 · 7:57pm ET

The trial targets ulcerative colitis treatment.

Max move

+61.1%

High of day $2.90

Sparker timei

7:57pm ET

PALI · Jan 15, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Palisade Bio, Inc. (Nasdaq: PALI) has completed all five single ascending dose (SAD) cohorts and initiated multiple ascending dose (MAD) cohorts in its Phase 1a/b trial of PALI-2108. The trial is designed to evaluate the safety, tolerability, and pharmacokinetics of PALI-2108 in patients with ulcerative colitis.

The company announced the progression of the trial, marking a significant step in the development of PALI-2108. No specific amounts or filings were disclosed in the announcement.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time PALI sparks.

Download Sniper App →

Catch the next PALI-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →